Brookline Capital Management Weighs in on MNPR Q2 Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Equities research analysts at Brookline Capital Management raised their Q2 2025 earnings estimates for shares of Monopar Therapeutics in a report released on Tuesday, May 13th. Brookline Capital Management analyst K. Dolliver now forecasts that the company will post earnings of ($0.55) per share for the quarter, up from their previous forecast of ($0.81). The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share. Brookline Capital Management also issued estimates for Monopar Therapeutics’ Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($1.06) EPS and FY2025 earnings at ($2.53) EPS.

Monopar Therapeutics (NASDAQ:MNPR) last released its earnings results on Tuesday, May 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.27.

Several other equities analysts have also recently weighed in on the stock. Piper Sandler reissued an “overweight” rating and issued a $76.00 target price on shares of Monopar Therapeutics in a research note on Wednesday, March 19th. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Monopar Therapeutics in a research report on Tuesday, April 1st. Finally, Jones Trading restated a “hold” rating on shares of Monopar Therapeutics in a research note on Wednesday, April 2nd.

Monopar Therapeutics Stock Up 6.6%

MNPR stock opened at $39.55 on Friday. The company has a market cap of $241.85 million, a price-to-earnings ratio of -20.08 and a beta of 1.11. Monopar Therapeutics has a twelve month low of $1.72 and a twelve month high of $54.30. The business has a 50 day moving average price of $37.34 and a two-hundred day moving average price of $31.48.

Institutional Trading of Monopar Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. acquired a new stake in shares of Monopar Therapeutics during the fourth quarter worth $45,000. RA Capital Management L.P. bought a new position in Monopar Therapeutics during the fourth quarter worth about $11,247,000. Geode Capital Management LLC increased its position in Monopar Therapeutics by 174.4% during the fourth quarter. Geode Capital Management LLC now owns 38,596 shares of the company’s stock worth $849,000 after acquiring an additional 24,530 shares during the period. Janus Henderson Group PLC acquired a new stake in Monopar Therapeutics in the 4th quarter worth about $23,435,000. Finally, ADAR1 Capital Management LLC bought a new stake in Monopar Therapeutics in the 4th quarter valued at about $2,861,000. 1.83% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, major shareholder Tactic Pharma Llc sold 33,334 shares of the business’s stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $35.00, for a total transaction of $1,166,690.00. Following the completion of the sale, the insider now owns 822,255 shares in the company, valued at $28,778,925. The trade was a 3.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 20.50% of the stock is owned by insiders.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.